Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer

Andrea Alimonti, Chiara Nardoni, Paola Papaldo, Gianluigi Ferretti, Maria Pia Caleno, Paolo Carlini, Alessandra Fabi, Debora Rasio, Aldo Vecchione, Francesco Cognetti

Research output: Contribution to journalArticlepeer-review


Ixabepilone (Ix) (BMS-247550®) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones. In pre-clinical studies, Ix has shown anticancer activity against several cancer types, including paclitaxel-resistant models, both in vitro and in vivo. The major toxicities associated with Ix are myelosuppression, sensory neuropathy and neutropenia. Other minor side-effects include asthenia/fatigue, stomatitis, anorexia, alopecia, skin reaction, hypersensitivity reactions and a fluid-retention syndrome. Although Ix is functionally correlated to taxanes, no previous evidence exists regarding Ix-related nail disorders. Here, we report a case of a 59-year-old woman treated with Ix at 40 mg/m2 day 1 q 21 days who, after 8 cycles of therapy, developed onycholysis and subungual hemorrhagic bullas in the fingernails.

Original languageEnglish
Pages (from-to)3531-3532
Number of pages2
JournalAnticancer Research
Issue number5
Publication statusPublished - Sep 2005


  • Breast cancer
  • Ixabepilone
  • Nail disorders

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer'. Together they form a unique fingerprint.

Cite this